Dual GIP/GLP-1 receptor agonist · Also known as Mounjaro, Zepbound
A dual-action peptide targeting both GIP and GLP-1 receptors. Shows even greater weight loss potential than semaglutide in head-to-head trials.
Tirzepatide represents the next generation of metabolic peptides by acting on two incretin receptors simultaneously. Clinical trials have demonstrated average weight reductions of up to 22.5% of body weight, making it the most effective weight loss peptide currently available.
Unlike semaglutide which only targets GLP-1 receptors, tirzepatide activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. This dual action enhances insulin sensitivity, reduces appetite through complementary pathways, and may also improve fat metabolism more effectively than targeting either receptor alone.
2.5 mg/week
Weeks 1-410-15 mg/week
After titration periodMost side effects tend to improve as your body adjusts.